Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Sotatercept

Generic Name: Sotatercept

Brand Names: Winrevair

Drug Type: Biotech

CAS Number: 1001080-50-7

Unique Ingredient Identifier: 0QI90BTJ37

Overview

Sotatercept has been used in trials studying the supportive care and treatment of Anemia, Leukemia, Solid Tumors, Bladder Cancer, and multiple myeloma, among others.

Background

Sotatercept has been used in trials studying the supportive care and treatment of Anemia, Leukemia, Solid Tumors, Bladder Cancer, and multiple myeloma, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)

Phase 1

Not yet recruiting

Posted: 2025/04/16

Sponsor:Merck Sharp & Dohme ...

ID:NCT06930664

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

Phase 2

Recruiting

Posted: 2025/04/13

Sponsor:Merck Sharp & Dohme ...

ID:NCT06925750

A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021)

Phase 1

Completed

Posted: 2025/02/25

Sponsor:Merck Sharp & Dohme ...

ID:NCT06843460

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

Phase 2

Recruiting

Posted: 2025/02/07

Sponsor:Merck Sharp & Dohme ...

ID:NCT06814145

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

Phase 2

Recruiting

Posted: 2024/10/30

Sponsor:Merck Sharp & Dohme ...

ID:NCT06664801

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 60MG (VIAL ONLY)

Manufacturer:Patheon Italia S.p.A

Form:INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Strength:60mg

Online:Yes

Approved: 2024/09/20

Approval:SIN17094P

WINREVAIR® POWDER FOR SOLUTION FOR INJECTION 45MG (VIAL ONLY)

Manufacturer:Patheon Italia S.p.A

Form:INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Strength:45mg

Online:Yes

Approved: 2024/09/20

Approval:SIN17093P

Related News

ATS 2025 Conference to Showcase Groundbreaking Pulmonary Research and Patient-Centered Initiatives

10 days ago

The American Thoracic Society (ATS) 2025 International Conference in San Francisco will feature cutting-edge research across pulmonary, critical care, and sleep medicine, drawing over 10,000 attendees from 85 countries.

CDMO Market Report: Key Regulatory Approvals and Clinical Advances in March-April 2025

a month ago

Multiple CDMOs secured significant contract manufacturing opportunities as regulatory bodies approved new indications for established drugs, particularly in oncology and rare diseases.

Merck's WINREVAIR Shows Promising Phase 3 Results for Pulmonary Arterial Hypertension Treatment

2 months ago

Merck's Phase 3 ZENITH trial for WINREVAIR demonstrated promising results for treating pulmonary arterial hypertension, adding to the company's growing therapeutic portfolio.

Merck to Present Phase 3 ZENITH Trial Results for WINREVAIR in High-Risk PAH Patients at ACC.25

2 months ago

Merck will present late-breaking data from the Phase 3 ZENITH trial evaluating WINREVAIR (sotatercept-csrk) in high-risk pulmonary arterial hypertension patients, which was concluded early due to overwhelming efficacy.

Pharmaceutical Industry Braces for $236 Billion Patent Cliff by 2030: Strategic Responses from Major Players

3 months ago

The global pharmaceutical industry faces a $236 billion patent cliff between 2025-2030, with nearly 70 blockbuster drugs losing exclusivity and exposing major companies to significant revenue losses.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy